Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | OXTR | P30559 | 2/20 | 0.30 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30615551 | 1.00 | F2 (0.38) | F2DGAT1HDAC1HDAC8HDAC6 | |
| SCHEMBL21464146 | 0.87 | DGAT1 (0.39) | F2DGAT1OXTRAVPR1A | |
| SCHEMBL18530409 | 0.86 | F2 (0.38) | F2DGAT1SSTR4 | |
| SCHEMBL16943188 | 0.82 | SSTR4 (0.39) | F2HDAC1HDAC8HDAC6SSTR4 | |
| SCHEMBL30202341 | 0.81 | F2 (0.36) | F2HDAC1HDAC8HDAC6SSTR4 | |
| SCHEMBL30692775 | 0.81 | F2 (0.36) | F2HDAC1HDAC8HDAC6SSTR4 | |
| SCHEMBL17336609 | 0.80 | SSTR4 (0.38) | F2HDAC1HDAC8HDAC6SSTR4 | |
| SCHEMBL7982682 | 0.79 | F2 (0.40) | F2DGAT1 | |
| SCHEMBL30202140 | 0.78 | F2 (0.35) | F2HDAC1HDAC8HDAC6SSTR4 | |
| SCHEMBL30692805 | 0.78 | F2 (0.35) | F2HDAC1HDAC8HDAC6SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| EP-3774739-B1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC (JP) | 2022-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | F2 3784/4885DGAT1 4461/4885HDAC1 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.